Anti-inflammatory agents

Jun 15, 2020

Lilly Begins a Phase 3 Clinical Trial with Baricitinib for Hospitalized COVID-19 Patients

Jun 03, 2020

EULAR 2020: Lilly Shares New Data for Olumiant® in Rheumatoid Arthritis and Systemic Lupus Erythematosus

Apr 09, 2020

PHA121, the first orally available bradykinin B2-receptor antagonist, shows clinically relevant activity in a translational in vivo model

Mar 16, 2020

Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata